Last reviewed · How we verify

NCT06740877

Skeletal Muscle Index and a Neuromuscular Blocking Agent

Not yet recruiting Last updated 18 December 2024
What this trial tests

trial in Neuromuscular Blockade in 90 participants. Not yet recruiting.

Timeline
25 December 2024
Primary endpoint
25 December 2025
25 December 2026

Quick facts

Lead sponsorSeoul National University Bundang Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment90
Start date25 December 2024
Primary completion25 December 2025
Estimated completion25 December 2026

Conditions studied

Sponsor

Seoul National University Bundang Hospital

Who can join

Adults 19 to 80, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With the recent development of image analysis, it has become possible to measure the skeletal muscle index representing the subject's muscle mass from preoperative computed tomography (CT) images. Therefore, in this study, the investigators quantify the skeletal muscle index from preoperative CT images and analyze the correlation with the dose of neuromuscular blocking agent, rocuronium, required for maintaining deep neuromuscular blockade.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuromuscular Blockade

Currently open trials in the same condition.

Other Seoul National University Bundang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing